{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071839","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.506312+00:00","generated_at":"2026-05-21T04:53:36.364750+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aura Biosciences Q1 net loss $27.5M; appoints Tony Gibney as CFO; Phase 3 CoMpass enrollment may complete by end 2025","bullets":["Net loss $27.5M for Q1 2025 vs $19.7M in Q1 2024; R&D expenses rose to $23.3M from $17.1M.","Cash and marketable securities $128.0M as of March 31, 2025; runway into second half of 2026.","Appointed Tony Gibney as Chief Financial and Business Officer effective May 13, 2025; he brings 30+ years biotech and investment banking experience.","Phase 3 CoMpass trial in early-stage choroidal melanoma actively enrolling; enrollment may complete as early as end 2025.","First patient enrolled in multi-dose Phase 1b/2 trial of bel-sar in NMIBC; initial data at 3 months expected by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071839","json":"https://secwatch.observer/filing/0000950170-25-071839.json","markdown":"https://secwatch.observer/filing/0000950170-25-071839.md","text":"https://secwatch.observer/filing/0000950170-25-071839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/aura-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:53:36.364750+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e284e3847","claim":"Anthony Gibney was appointed as Chief Financial and Business Officer at Aura Biosciences, Inc..","evidence_excerpt":"Appointment of Chief Financial and Business Officer Effective as of May 13, 2025 (the “Effective Date”), the Board of Directors of the Company appointed Anthony Gibney as the Company’s Chief Financial and Business Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial and Business Officer"}],"fact_type":"executive_change"},{"claim_id":"d08f36e77f","claim":"Amy Elazzouzi changed role as Senior Vice President, Finance at Aura Biosciences, Inc..","evidence_excerpt":"Beginning on the Effective Date, Amy Elazzouzi, the Company’s Senior Vice President, Finance, will cease serving as the Company’s principal financial officer and continue as the Company’s principal accounting officer and Mr. Gibney will serve as the Company’s principal financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1501796/000095017025071839/0000950170-25-071839-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased serving as principal financial officer"},{"label":"Role","value":"Senior Vice President, Finance"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}